SIO2018 will include keynote presentations from Andrew Weil, MD; Patricia Ganz, MD; and Eran Ben-Ayre, MD. 

andrew Weil head shot

Andrew Weil, MD
Integrative Oncology, Present and Future
Saturday, October 27, 2018 - 8:50 - 10:05 am MST

Demand for practitioners of Integrative Oncology is high, motivated largely by awareness of the shortcomings of conventional cancer treatment. In the not-distant future, radiation therapy and chemotherapy will likely be obsolete, replaced by immunotherapy, gene therapy, antiangiogenesis therapy and other methods that better differentiate malignant cells from normal cells. The goals of IO should be: 1) to reduce the toxicity and increase the efficacy of conventional treatment, 2) to mobilize and enhance the body’s innate defenses in order to slow or halt progression of cancer and reduce risk of recurrence, and 3) to promote general health and improve overall quality of life.

In response to consumer demand for IO, many cancer treatment centers now advertise that they offer integrative care. Usually, what they offer are noncontroversial complementary services, such as nutritional counseling, massage, and stress management training. They are not willing to recommend or endorse the use of natural products like astragalus and Asian mushrooms, despite good evidence for safety and efficacy.

I will describe my experience at Beijing’s Guang’anmen Hospital, a modern medical center entirely devoted to Integrative Medicine, whose largest department is oncology. All cancer patients there are treated with surgery, radiation, and chemotherapy as indicated as well as nutritional therapy, massage, acupuncture and, especially, sophisticated Chinese herbal therapy to accomplish the important goals of IO.

Conventionally trained oncologists tend to reject much of this as lacking an evidence base or having the potential to cause harm or interfere with standard treatment. In addition to offering better, more comprehensive care to patients, we must work to broaden the training of oncologists.

About Dr. Weil

Andrew Weil, M.D., is a world-renowned leader and pioneer in the field of integrative medicine. Combining a Harvard education and a lifetime of practicing natural and preventive medicine, Dr. Weil is the founder and director of the University of Arizona Center for Integrative Medicine (AzCIM) in Tucson, where he also serves as a Clinical Professor of Medicine and Professor of Public Health as well as the Lovell-Jones Professor of Integrative Rheumatology.

He is a best-selling author of 15 books on healthy living, including the recent Mind Over Meds; Fast Food, Good Food; True Food; Spontaneous Happiness; Healthy Aging; and 8 Weeks to Optimum Health. Oxford University Press is currently producing the Weil Integrative Medicine Library, a series of volumes for clinicians in various medical specialties. The first of these, Integrative Oncology (co-edited with Dr. Donald Abrams) appeared in 2009 (2d. ed. 2014). Since 2009, Integrative Psychiatry, Integrative Pediatrics, Integrative Women’s Health (2d. ed. 2015), Integrative Rheumatology, Integrative Cardiology, Integrative Gastroenterology, Integrative Nursing, Integrative Men’s Health, Integrative Dermatology, Integrative Pain Management, Integrative Environmental Medicine, Integrative Preventive Medicine, and Integrative Psychiatry and Brain Health have been published. More volumes are in progress.

Dr. Weil also serves as the editorial director of, the leading online resource for healthy living based on the philosophy of integrative medicine, and pens the popular Dr. Andrew Weil’s Self Healing monthly newsletter and a regular column in Prevention magazine. Dr. Weil is the founder and Chairman of the Weil Foundation, and the founder and co-Chairman of Healthy Lifestyle Brands. He is also a founder and partner of the growing group of True Food Kitchen restaurants. In 2017, he joined Seabourn and The Onboard Spa by Steiner in their “Spa and Wellness with Dr. Andrew Weil” mindful-living program, offered on all of its cruise ships.



Patricia Ganz, MD
Symptom Science in Cancer Survivors: Advances in Biology and Management 
Sunday, October 28, 2018 - 8:00 - 9:15 am MST

Dr. Ganz will review information on the growing number of cancer survivors, and the evidence for the symptom burden associated with cancer treatments. Because there are now more than 15 million cancer survivors in the US, and nearly 30 million worldwide, understanding the biology and management of common symptoms is critical. She will focus on describing emerging evidence regarding the association of common symptoms of fatigue, insomnia and cognitive difficulties with treatment-associated inflammatory biology. Further, She will show research from her laboratory and others that find that various beneficial integrative oncology approaches are associated with improvements in inflammatory biology. Understanding the biological mechanisms underpinning common symptoms in cancer survivors is a first step in finding pharmacological and non-pharmacological approaches to their alleviation.

About Dr. Ganz

Patricia A. Ganz, MD, Distinguished Professor of Medicine at David Geffen School of Medicine and Professor of Health Policy & Management, Jonathan and Karin Fielding School of Public Health at UCLA; Director, Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.

Patricia A. Ganz, M.D., a medical oncologist, has been a member of the faculty of the UCLA School of Medicine since 1978 and the UCLA School of Public Health since 1992. Since 1993 she has been the Director of Cancer Prevention and Control Research at the Jonsson Comprehensive Cancer Center. In 1999 she was awarded an American Cancer Society Clinical Research Professorship for “Enhancing Patient Outcomes across the Cancer Control Continuum.” Dr. Ganz was elected to the Institute of Medicine (IOM) in 2007, now National Academy of Medicine. She served on the National Cancer Institute Board of Scientific Advisors from 2002-2007 and on the American Society of Clinical Oncology (ASCO) Board of Directors from 2003-2006. She received the American Cancer Society Medal of Honor in 2010. Dr. Ganz is a pioneer in the assessment of quality of life in cancer patients, and has focused much of her clinical and research efforts in the areas of breast cancer and its prevention. At the Jonsson Comprehensive Cancer Center, she leads the scientific program focused on Patients and Survivors. Her major areas of research include cancer survivorship and the late effects of cancer treatment, measurement of patient-reported outcomes in clinical treatment trials, and quality of care for cancer patients. In July 2017, Dr. Ganz became Editor-in-Chief of the Journal of the National Cancer Institute (JNCI).


Eran Ben Arye MD

Eran Ben-Arye, MD 
Integrative Oncology in the Middle East 
Monday, October 29, 2018 - 8:00 - 9:15 am MST

The Middle East is a unique setting in which one can explore the interchange between cross-cultural traditional medicine and supportive cancer care, especially within the context of integrative oncology. The diversity of Middle Eastern medical culture is particularly evident in Israel, where Arab and Islamic traditional herbal medicine – whose roots can be traced back to ancient Greek, Chinese, and Ayurvedic sources – interact with the Western-oriented approach of complementary medicine

The keynote lecture will present the phenomenon of an increasing interest in the field of integrative oncology in Israel and throughout the Middle East, which entails the designing of a patient-tailored and cultural-sensitive bio-psycho-social-spiritual model of holistic care. This approach is being examined within a pragmatic research design, in which the patient’s preference and health belief model plays an important role in the creation of a shared decision-making process, where the integrative physician and the patient co-establish treatment goals and program. The non-judgmental setting is also evidence-based, and is geared toward facilitating better communication with the patient’s oncology health care practitioners. The integrative oncology model needs to expand beyond the existing frameworks of complementary and traditional medicine, exploring the existence of synergy with other patient-centered medical disciplines such as palliative care and family medicine. It is with these goals in mind that a multi-national and interdisciplinary collaboration has been created, as part of the academic activities of the Middle-East Research Group in Integrative Oncology (MERGIO), within the Middle-East Cancer Consortium.

About Dr. Ben Arye

Eran Ben-Arye has an MD degree from the Faculty of Medicine of the Hebrew University of Jerusalem. He specialized in family medicine at the Department of Family Medicine, The Bruce Rappaport Faculty of Medicine, The Technion, Israel. Prof. Ben-Arye developed and instructed in a complementary medicine education program in the Division of Complementary Medicine, University of Maryland, Baltimore, USA. He is the co-founder and director of the Unit of Complementary and Traditional Medicine at the Department of Family Medicine, Haifa, and the director of the Integrative Oncology Program within the Haifa and Western Galilee Oncology Service, Lin Medical Center, Clalit Health Services. Prof. Ben-Arye is a Clinical Associate Professor at the Bruce Rappaport Faculty of Medicine, The Technion, and is a founding member and former Chairperson of the Israel Society for Complementary Medicine of the Israel Medical Association.

His research interests include integrative and complementary medicine, family medicine, integrative oncology, medical education, doctor-patient communication, evidence-based medicine and research, and traditional and cross-cultural medicine. He has authored and co-authored 140 manuscripts in peer-reviewed journals and 8 chapters in oncology textbooks. Prof. Ben-Arye has constructed and co-conducted more than 10 clinical studies in the area of complementary and integrative medicine, including three randomized controlled studies.

Professor Ben-Arye has been involved in promoting Integrative Oncology throughout the Middle East. Together with Professor Michael Silbermann, director of the Middle East Cancer Consortium (MECC), he co-founded the Middle-East Research Group in Integrative Oncology (MERGIO), regional, multi-national and interdisciplinary research collaboration.